Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary.

Fischer, Jan A.; Tobler, Paul H.; Kaufmann, Marika; Born, Walter; Henke, H.; Cooper, Paul E.; Sagar, Stephen M.; Martin, Joseph B.

doi:10.1073/pnas.78.12.7801

Cited by 172 publications

(74 citation statements)

References 34 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Calcr has been demonstrated in a variety of tissues not directly involved in the regulation of Ca 2+ homeostasis. Especially, expression of Calcr has been observed in the brain, suggesting that it has distinct functions also in the central nervous system (CNS) (Fischer et al 1981). In the CNS, calcitonin is thought to enhance the secretion of anterior pituitary hormones and inhibit appetite and gastric acid secretion (Pondel 2000).…”

Section: Resultsmentioning

confidence: 99%

Calcr, a brain-specific imprinted mouse calcitonin receptor gene in the imprinted cluster of the proximal region of chromosome 6

et al. 2003

View full text Add to dashboard Cite

Expressed sequence tags (ESTs) in the human chromosome 7q21-q31 region were recently used to screen for allelic expression bias in monochromosomal hybrids retaining a paternal or maternal human chromosome 7. Six candidate imprinted genes were identified. In this study, we investigated parent-of-originspecific expression profiles of their mouse homologues in the proximal region of chromosome 6. An imprinting analysis, using F1 mice from reciprocal crosses between the B6 and JF strains, demonstrated that the mouse calcitonin receptor gene (Calcr) was expressed preferentially from the maternal allele in brain, whereas no allelic bias was detected in other tissues. Our results indicate that Calcr is imprinted in a tissue-specific manner, with a predominant expression from the maternal allele in the brain.

show abstract

Section: Resultsmentioning

confidence: 99%

Calcr, a brain-specific imprinted mouse calcitonin receptor gene in the imprinted cluster of the proximal region of chromosome 6

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Like the CT receptor of other target cells or tissues, the placental CT receptor has a high affinity for salmon CT, the relative binding potencies of CTs derived from other species are maintained and non-related peptides do not bind. Furthermore, the placental receptor displays poorly reversible binding, characteristic of CT binding in all tissues studied [7,10,20,39,40].…”

Section: Discussionmentioning

confidence: 98%

“…Subsequent investigations have shown that the osteoclast [2][3][4][5] and renal tubular cells [6][7][8][9] are major target cells. Nevertheless, a number of other tissues possess CT receptors, including brain [10][11][12], lung [13], testes [14], and trout gill [15] as well as cell lines derived from a wide range of neoplasias including human breast [16], lung [17], and renal carcinoma [18], leukaemia [19,20], teratocarcinoma [21] and osteogenic sarcoma [22]. However, none of these has provided a substantial source of receptor because of either low specific binding activity, scarcity of tissue, or both.…”

Section: Introductionmentioning

confidence: 99%

Human placental calcitonin receptors

Nicholson

D’Santos

Evans

et al. 1988

Biochemical Journal

View full text Add to dashboard Cite

Receptors for the hypocalcaemic hormone, calcitonin (CT), have been identified in a membrane fraction prepared from term human placentae. Binding of 125I-labelled salmon CT (125I-sCT) to the membranes was time- and temperature-dependent, saturable (Bmax. 58 +/- 11 fmol/mg of protein), of high affinity (Kd 80 +/- 21 pM) and poorly reversible. Species-specific CTs and CT analogues competed for 125I-sCT binding with potencies proportional to their known biological potencies. Various unrelated peptide hormones did not compete, indicating that receptor binding was specific for CT. Photoaffinity labelling using a derivatized biologically active sCT analogue, [Arg11,18,3-nitrophenylazide-Lys14]sCT, identified a receptor component of Mr approximately 85,000, comparable with findings in osteoclasts and other target cells. The presence of CT receptors in the human placenta supports other evidence that CT may have a role in the regulation of placental function.

show abstract

“…Secondly, it has been shown to increase ACTH, ß-endorphin and cortisol serum levels (21), indicating a possible role in modulation of the anterior pituitary function, but this is challenged in other studies (22). Thirdly, specific binding sites for salmon calcitonin have been found in the brain of animals (23,24) and humans (25), suggesting a central intrinsic analgesic effect; supported by the successful use of calcitonin as a subarachnoid or epidural injection in humans (26). Finally, calcitonin has been shown to potentiate the analgesic effect of opioids in animals (27).…”

Section: Discussionmentioning

confidence: 97%

Analgesic activity of high-dose intravenous calcitonin in cancer patients with bone metastases

Tsavaris

Kopterides²,

Kosmas³

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

Abstract. We undertook a prospective, nonrandomized study with the objective to evaluate the efficacy of salmon calcitonin (sCT) in controlling pain secondary to bone metastases. Our study population consisted of 45 cancer patients with bone metastases (26 men) with a mean age of 64 years (range, 48-70) who had completed chemotherapy, hormonal therapy and radiation therapy at least 30 days prior to enrollment in the study, and had intractable pain despite the use of common analgesics (acetaminophen, nonsteroidal anti-inflammatory agents, opioids) and bisphosphonates. The study medication was a 300-IU dose of sCT administered intravenously daily for 5 consecutive days and repeated every two weeks until no response was noticeable. The analgesic efficacy of sCT was evaluated by means of Huskisson's visual analogue scale and Keele's pain scale; the daily consumption of analgesic drugs and performance status were also monitored. None of the patients managed to completely discontinue the use of other analgesics, but 5 patients (11% of the total number) had an analgesic response that lasted 4 weeks and less than 5% of the patients continued to respond for 6 weeks. No significant side effects were observed. Our data show that intravenous calcitonin administered in a relatively high dose has a very limited therapeutic potential as an adjuvant analgesic for a short period of time in selected cancer patients with bone metastases.

show abstract

Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary.

Cited by 172 publications

References 34 publications

Calcr, a brain-specific imprinted mouse calcitonin receptor gene in the imprinted cluster of the proximal region of chromosome 6

Calcr, a brain-specific imprinted mouse calcitonin receptor gene in the imprinted cluster of the proximal region of chromosome 6

Human placental calcitonin receptors

Analgesic activity of high-dose intravenous calcitonin in cancer patients with bone metastases

Contact Info

Product

Resources

About